摘要
肝细胞癌是最常见的恶性肿瘤之一,死亡率高,预后不理想。近年来,应用分子靶向药物治疗肝癌取得重大突破,特别是多靶点、多激酶抑制药索拉非尼在肝癌的治疗取得的成功。
Hepatocellular carcinoma is one of the most malignant tumors in the world. HCC patients often have a high death rate and a poor clinical outcome. In recent years, targeted molecular therapy, an important breakthrough in tumor therapies, has achieved success in the treatment of hepatocellular carcinoma. Multi-target, multi-kinase inhibitor sorafenib gets success in hepatocellular carcinoma treatment.
出处
《临床药物治疗杂志》
2012年第3期24-26,共3页
Clinical Medication Journal
基金
国家自然科学基金项目(No.81101877)
